Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia
Clinical trial NCT05554913 · COMPLETED
Trial details
- NCT number
- NCT05554913
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-08
- Primary completion
- 2024-02-20
- Enrollment
- 63
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.